Fondaparinux
As of the edition of 20 October 2026, Fondaparinux is an oligosaccharide: marketed, first approved in 2001 (US); acts on SERPINC1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Oligosaccharide
- Brand name
- Arixtra
- First approved
- 7 December 2001 (US)
- Approvals on record
- 8 in 4 regions
- Holder of the most recent approval
- ASPEN PHARMA INDÚSTRIA FARMACÊUTICA LTDA; 4 holders in all
- Withdrawn from market
- 11 March 2008 (in some regions)
- Registered trials
- 49, 14 stopped early
- Disease areas
- Heart and blood vessels; Lungs and airways; Pregnancy and women's health; Urinary and reproductive; Cancer; Blood and lymph
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Fondaparinux.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SERPINC1 | Antithrombin-III | P01008 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 15 | 12 | 0 | 2 |
| Phase 1 | 5 | 3 | 0 | 2 |
| Phase 2 | 5 | 3 | 0 | 2 |
| Phase 3 | 16 | 11 | 0 | 3 |
| Phase 4 | 8 | 3 | 0 | 5 |
| All trials | 49 |